Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.

ABSTRACT:

Background

In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to other patients, and their daily administration was resource intensive. An alternative treatment in the form of subcutaneous depot buprenorphine became a viable option following a safety trial in 2020 - the UNLOC-T study. Depot preparation demonstrated advantages over current treatments as more difficult to divert and requiring fewer administrations. This paper reports the results of economic modelling of staffing costs in medication administration comparing depot buprenorphine, methadone, and sublingual buprenorphine provision in UNLOC-T trial facilities

SUBMITTER: Ling R 

PROVIDER: S-EPMC9644557 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature